WASHINGTON, Oct 14 (Reuters) - A U.S. Food and Drug Administration advisory panel on Wednesday :
* said in 12-1 vote that Acorda Therapeutics Inc should be required to test lower doses of its walking drug for multiple sclerosis patients
* said such tests of fampridine should not be required before approval
* Said in 10-2 vote that fampridine can be considered safe under certain conditions. One panelist abstained.
* The FDA panel of outside advisers earlier said the drug was effective. The agency will weigh the recommendations before later making an approval decision.
(Company news desk in Washington; +1 202 898 8400, washington.newsroom@thomsonreuters.com) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* said in 12-1 vote that Acorda Therapeutics Inc should be required to test lower doses of its walking drug for multiple sclerosis patients
* said such tests of fampridine should not be required before approval
* Said in 10-2 vote that fampridine can be considered safe under certain conditions. One panelist abstained.
* The FDA panel of outside advisers earlier said the drug was effective. The agency will weigh the recommendations before later making an approval decision.
(Company news desk in Washington; +1 202 898 8400, washington.newsroom@thomsonreuters.com) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.